AI Stock Analysis - aTyr Pharma (ATYR)
Analysis generated February 19, 2026.
aTyr Pharma is a biopharmaceutical company engaged in discovering and developing innovative medicines based on novel biological pathways. The company focuses on achieving high impact in the therapeutic areas it targets, developing diverse pipeline products. This business strategy is aligned with emerging trends in biotechnology, emphasizing clinical excellence and targeted medical breakthroughs.
Stock Alerts - aTyr Pharma (ATYR)
 |
aTyr Pharma | March 10 Price is up by 7.8% in the last 24h. |
|
aTyr Pharma | March 9 Price is up by 7.8% in the last 24h. |
|
aTyr Pharma | March 6 Price is down by -6.5% in the last 24h. |
|
aTyr Pharma | March 5 Price is down by -6.7% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for aTyr Pharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 82 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 171 | Sign up | Sign up | Sign up |
| Instagram Followers | 120 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 31 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 13,357 | Sign up | Sign up | Sign up |
| X Followers | 1,572 | Sign up | Sign up | Sign up |
| X Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 74 | Sign up | Sign up | Sign up |
| Linkedin Employees | 78 | Sign up | Sign up | Sign up |
About aTyr Pharma
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
| Price | $0.94 |
| Target Price | Sign up |
| Volume | 1,556,271 |
| Market Cap | $81M |
| Year Range | $0.65 - $6.61 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
12 Health Care Stocks Moving In Wednesday's After-Market SessionMarch 4 - Benzinga |
ViroMissile Appoints Michael G. Wood as Chief Business OfficerJanuary 15 - GlobeNewswire |
|
Bio/Pharmaceutical Outsourcing Market Research Report, November 2025: Transforming US Drug Access and Production - MFN Pricing Deals and Historic Manufacturing InvestmentsJanuary 6 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 190,000 | 22M | -22M | -26M | -26M | -0.260 |
| Q2 '25 | 0 | 390,000 | -390,000 | -20M | -20M | -0.220 |
| Q1 '25 | 0 | 380,000 | -380,000 | -15M | -15M | -0.170 |
| Q4 '24 | 0 | 12M | -12M | -15M | -16M | -0.181 |
| Q3 '24 | 0 | 390,000 | -390,000 | -17M | -18M | -0.228 |
Insider Transactions View All
| DENYES NANCY filed to sell 33,124 shares at $1. February 4 '26 |
| Broadfoot Jill Marie filed to sell 37,296 shares at $1. February 4 '26 |
| Shukla Sanjay filed to sell 153,553 shares at $1. February 4 '26 |
| SCHIMMEL PAUL filed to buy 1,413,023 shares at $0.9. October 9 '25 |
| SCHIMMEL PAUL filed to buy 1,095,024 shares at $0.9. October 9 '25 |
Similar companies
Read more about aTyr Pharma (ATYR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - aTyr Pharma
The Market Cap of aTyr Pharma is $81M.
Currently, the price of one share of aTyr Pharma stock is $0.94.
The ATYR stock price chart above provides a comprehensive visual representation of aTyr Pharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling aTyr Pharma shares. Our platform offers an up-to-date ATYR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, aTyr Pharma (ATYR) does not offer dividends to its shareholders. Investors interested in aTyr Pharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of aTyr Pharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
